A retrospective study compared progression-free and overall survival of hyperthermic intraperitoneal chemotherapy with conventional intraperitoneal chemotherapy in patients with ovarian cancer.

Amber and her family in the Volkswagen convertible she bought after learning she was cancer-free Amber used to live her life with anxiety and fear—always trying to stay within her comfort zone. She ...

In over 400 women at first epithelial ovarian cancer recurrence, those who received HIPEC had a median OS of 54.3 months compared with 45.8 months for those who did not (HR 0.73, 95% CI 0.56-0.96, P=0 ...

SCS combined with HIPEC may improve overall survival in PSROC patients compared to SCS alone, with a statistically significant benefit observed. The risk of severe complications, including anemia and ...